DK
Highly rated in
16
conditions

Dr. Donald B. Kohn

Westwood Pediatrics
Los Angeles, CA
Highly rated in
16
conditions
Specialties:Pediatric Hematology Oncology | Pediatrics
Age:69
Clinical Trials:Currently Recruiting for 1 Trial
Accepts:New Patients
Highly rated in
16
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Donald B. Kohn's experience treating your condition:
About Dr. Donald B. Kohn

Donald Kohn is a Pediatric Hematologist Oncology specialist and a Pediatrics expert in Los Angeles, California. Kohn is highly rated in 16 conditions, according to our data. His top areas of expertise are Adenosine Deaminase Deficiency, Severe Combined Immunodeficiency (SCID), Bare Lymphocyte Syndrome, Omenn Syndrome, and Bone Marrow Transplant. He is licensed to treat patients in California. Kohn is currently accepting new patients.

His clinical research consists of co-authoring 175 peer reviewed articles and participating in 11 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Donald B. Kohn it is best to call his office and ask if your insurance is accepted.

Dr. Donald B. Kohn accepts the following insurance:

  •  Ambetter
Locations
200 Ucla Medical Plz, Los Angeles, CA 90095
Background & Education
Specialties
Pediatric Hematology Oncology
Pediatrics
Licenses
Pediatric Hematology-Oncology in CA
Hospital Affiliations
Ronald Reagan UCLA Medical Center
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials
Clinical Research Study of Autologous Stem Cell Transplantation for Sickle Cell Disease (SCD) Using Peripheral Blood CD34+ Cells Modified With the Lenti/G-βAS3-FB Lentiviral Vector
Enrollment Status: Recruiting
Publish Date: April 12, 2022
Intervention Type: Biological
Study Drug: ?AS3-FB vector transduced peripheral blood CD34+ cells
Study Phase: Phase 1/Phase 2
Efficacy and Safety of Cryopreserved Formulation of Autologous CD34+ Hematopoietic Stem Cells Transduced Ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for Human ADA Gene in Subjects With Severe Combined Immunodeficiency Due to ADA Deficiency
Enrollment Status: Completed
Publish Date: August 03, 2022
Intervention Type: Genetic, Drug
Study Phase: Phase 1/Phase 2
Autologous Transplantation of Bone Marrow CD34+ Stem/Progenitor Cells After Addition of a Normal Human ADA Complementary DNA (cDNA) by the EFS-ADA Lentiviral Vector for Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency (ADA-SCID)
Enrollment Status: Completed
Publish Date: August 03, 2022
Intervention Type: Drug, Genetic
Study Phase: Phase 1/Phase 2
A Single Arm, Open Label Clinical Study to Enable Process Validation of Commercial Grade Ex Vivo Hematopoietic Stem Cell Gene Therapy (OTL-101) in Subjects With Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency (ADA-SCID)
Enrollment Status: Withdrawn
Publish Date: August 03, 2022
Intervention Type: Biological
Study Phase: Phase 2/Phase 3
A Two-Part, Phase I/II, Non Randomized, Multicenter, Open-Label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease
Enrollment Status: Active, not recruiting
Publish Date: August 03, 2022
Intervention Type: Biological
Study Drug: Lentiviral G1XCGD Gene Therapy
Study Phase: Phase 1/Phase 2
Multi-site Phase I/II Trial Evaluating the Treatment of SCID-X1 Patients With Retrovirus-mediated Gene Transfer
Enrollment Status: Active, not recruiting
Publish Date: July 22, 2022
Intervention Type: Biological
Study Drugs: BusulfanBone Marrow Cell Infusion
Study Phase: Phase 1/Phase 2
A Phase I Clinical Trial for Gene Therapy in Infantile Malignant Osteopetrosis (IMO) to Evaluate the Safety and Preliminary Efficacy of Autologous CD34+ Enriched Cells Transduced With a LV Vector Encoding the TCIRG1 Gene
Enrollment Status: Terminated
Publish Date: July 13, 2022
Intervention Type: Biological
Study Drug: Autologous CD34-Enriched TCIRG1 Transgene-Transduced Hematopoietic Stem Cells
Study Phase: Phase 1
Transplantation of CRISPRCas9 Corrected Hematopoietic Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease
Enrollment Status: Not yet recruiting
Publish Date: April 27, 2022
Intervention Type: Drug
Study Drug: CRISPR_SCD001
Study Phase: Phase 1/Phase 2
Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I): A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of the Infusion of Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector Encoding the ITGB2 Gene
Enrollment Status: Active, not recruiting
Publish Date: November 22, 2021
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
Enrollment Status: Enrolling by invitation
Publish Date: September 02, 2021
MND-ADA Transduction of CD34+ Cells From the Bone Marrow Of Children With Adenosine Deaminase (ADA)-Deficient Severe Combined Immunodeficiency (SCID): Effect of Discontinuation of PEG-ADA and Marrow Cytoreduction With Busulfan
Enrollment Status: Completed
Publish Date: April 23, 2021
Intervention Type: Biological
Study Phase: Phase 2
View 10 Less Clinical Trials -
176 Total Publications
Diverse Approaches to Gene Therapy of Sickle Cell Disease.
Journal: Annual review of medicine
Published: September 06, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
TM
Dr. Theodore B. Moore
Pediatric Hematology Oncology | Pediatrics
Highly rated in
12
conditions
Pediatric Hematology Oncology
Pediatrics

UCLA Health System

Children's Health Center

200 Ucla Medical Plz, 
Los Angeles, CA 

Theodore Moore is a Pediatric Hematologist Oncology specialist and a Pediatrics expert in Los Angeles, California. Moore has been practicing medicine for over 34 years and is highly rated in 12 conditions, according to our data. His top areas of expertise are Severe Combined Immunodeficiency (SCID), Bare Lymphocyte Syndrome, Omenn Syndrome, Bone Marrow Transplant, and Bone Marrow Aspiration. He is licensed to treat patients in California. Moore is currently accepting new patients.

LM
Dr. Leo Mascarenhas
Pediatric Hematology Oncology | Hematology | Oncology
Highly rated in
43
conditions
Pediatric Hematology Oncology
Hematology
Oncology

Childrens Hospital Los Angeles

4650 W Sunset Blvd, 
Los Angeles, CA 
 9.2 mi

Leo Mascarenhas is a Pediatric Hematologist Oncology specialist and a Hematologist in Los Angeles, California. Mascarenhas has been practicing medicine for over 33 years and is highly rated in 43 conditions, according to our data. His top areas of expertise are Rhabdomyosarcoma, Hepatoblastoma, Adult Soft Tissue Sarcoma, Bone Marrow Aspiration, and Bone Marrow Transplant. He is licensed to treat patients in California.

AW
Dr. Alan S. Wayne
Pediatric Hematology Oncology | Pediatrics
Highly rated in
5
conditions
Pediatric Hematology Oncology
Pediatrics

Childrens Hospital Los Angeles

4650 W Sunset Blvd, 
Los Angeles, CA 
 9.2 mi

Alan Wayne is a Pediatric Hematologist Oncology specialist and a Pediatrics expert in Los Angeles, California. Wayne has been practicing medicine for over 39 years and is highly rated in 5 conditions, according to our data. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Severe Combined Immunodeficiency (SCID), Adult T-Cell Leukemia, and Bone Marrow Transplant. He is licensed to treat patients in Maryland and California.